

Acknowledgement of Positive Carrier Screening Results: Donor 5981

I, the undersigned recipient, understand that this donor has tested **POSITIVE** as a carrier for the following condition(s):

- Congenital disorder of glycosylation type la (PMM2)
- Dystrophic epidermolysis bullosa (DEB)

I intend to use sperm samples from this donor for insemination or other assisted conception procedure(s).

I acknowledge that The Sperm Bank of California (TSBC) has made the donor's genetic testing results available to me and my medical providers, and that I have reviewed these results. I understand that TSBC **strongly recommends** that I review these genetic testing results with a Genetic Counselor and my medical providers. I understand that TSBC can refer me to genetic counseling services if desired.

I understand that recipient testing is strongly recommended when a donor has positive carrier screening results and that such testing can reduce but not eliminate risks.

I acknowledge that I personally assume all risks associated with use of semen samples provided by a donor who has tested **POSITIVE as a carrier for Congenital disorder of glycosylation type Ia (PMM2) and Dystrophic epidermolysis bullosa (DEB)**

On behalf of myself and my spouse, heirs, representatives, I hereby release and forever hold harmless TSBC and its current and former officers, directors, employees, attorneys, insurers, consultants, agents, and representatives (collectively "Releases") from any liability or responsibility whatsoever for any and all outcomes, and hereby release and forever discharge Releases from any and all actions, causes of action, demands, damages, losses, liabilities, suits, expenses, including attorneys' fees and costs, of whatever character, in law or in equity, whether currently known, suspected, unknown or unsuspected, matured or unmatured, arising out of my use of sperm donated by a donor who has tested **POSITIVE as a carrier for Congenital disorder of glycosylation type Ia (PMM2) and Dystrophic epidermolysis bullosa (DEB).** This release involves the waiver of all rights and benefits that I may have under California Civil Code section 1542, which states: "A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party."

Please select one of the following:

- □ I have been tested for the above named condition(s) and/or I plan to be tested prior to using the samples.
- □ I understand that TSBC **strongly recommends** that I discuss these results with a Genetic Counselor and my medical providers and consider testing for the above named condition(s). At this time I have **declined** testing and/or **do not anticipate being tested**.

I understand that if I transfer my vials (or embryos if applicable) to any other person, including my spouse, that TSBC requires that person (1) register with TSBC and (2) complete an **Acknowledgement of Positive Carrier Screening Results**.

I understand that any and all questions as to the legal interpretation, validity or any other aspect of this agreement shall be determined by the laws of the State of California, regardless of the location or residence of any of the parties.

Date



GENETIC TESTING: POSITIVE CARRIER STATUS

This donor tested **POSITIVE** as a carrier for one or more autosomal recessive conditions as described on the prior page and in the attached genetic testing results.

What does it mean to be a carrier?

<u>All people carry genetic mutations in their DNA</u>. Genetic testing can help to identify some, but not all, of these mutations. While this donor carries a mutation for one or more recessively inherited condition(s), offspring from this donor are not expected to be at risk of developing these condition(s) unless the recipient (or egg provider if different from the recipient) also carries a genetic mutation for the same condition(s). For this reason, we strongly encourage you to discuss carrier screening for yourself (or your egg provider) with your physician and a genetic counselor. Genetic testing can reduce but not eliminate risks.

What are my next steps?

1. Download the genetic test results and review with your medical providers

We **strongly recommend** that you discuss this donor's genetic test results with your physician **PRIOR TO SCHEDULING A SHIPMENT OR PICK-UP**, to confirm the donor is suitable for your use. Vials retrieved from the building cannot be exchanged or refunded. The donor's genetic test results are available for free download on the donor's page at <u>https://www.thespermbankofca.org/donor-catalog</u>.

2. We recommend scheduling a genetic counseling session.

A genetic counselor can explain the results in detail including the inheritance pattern, potential risks to your children, and the available testing options that you may want to consider for yourself (or your egg provider). Phone or in person consultations are available for a fee with TSBC's Genetic Counselors at San Francisco Genetic Counseling (<u>https://www.sfgenetics.org/</u>) or you can locate a genetic counselor at <u>www.findageneticcounselor.com</u>.

3. Complete and return the Acknowledgement of Positive Carrier Screening Results

TSBC requires that all recipients selecting this donor complete this acknowledgement form **PRIOR TO SCHEDULING A SHIPMENT OR PICK-UP**. Completing this form documents that you have been informed about this donor's genetic test results and that you are aware of TSBC's recommendation to discuss the genetic test results with your medical providers as noted above.

Reproductive Technologies, Inc. THE SPERM BANK OF CALIFORNIA

EXPANDED CARRIER SCREENING RESULTS DONOR 5981

Expanded carrier screening for 268 autosomal recessive conditions was completed by Invitae and reported on 04/01/2022.

The results were **POSITIVE** for **Congenital disorder of glycosylation type Ia (PMM2)** and **Dystrophic epidermolysis bullosa (DEB)**.

Donor 5981 is a carrier for these conditions.

Dystrophic epidermolysis bullosa (DEB) is a disease with autosomal recessive and autosomal dominant inheritance patterns. The specific mutation in COL7A1 for DEB is associated with the autosomal recessive form and likely follows the recessive pattern of inheritance.

It is strongly recommended that recipients who use this donor's sperm undergo carrier screening for these specific conditions.

Testing was negative for the remainder of genes screened.

Disease	Result	Residual risk to be a carrier
Congenital disorder of glycosylation type Ia (PMM2)	POSITIVE	n/a
Dystrophic epidermolysis bullosa	POSITIVE	n/a
Cystic Fibrosis	Negative	1 in 2,700
Spinal Muscular Atrophy	Negative: 2 copies exon 7 c.*3+80T>G variant not detected	1 in 784
HBB Hemoglobinopathies & Thalassemia	Negative	1 in 1,600
Alpha Thalassemia	Negative	1 in 241

Genetic screening tests can significantly reduce, but never completely eliminate, the chance that a person is a carrier for a particular disorder.

Please refer to the donor's Invitae expanded carrier test report for more information on the testing completed and the donor's results.

Please also see the Health Problems List for a summary of the information that this donor has provided to us regarding personal and family medical history.

Sincerely,

Janine Mash LCGC Certified Genetic Counselor San Francisco Genetic Counseling





Patient name: Sex assigned at birth: Gender:	5981 DONOR Male	Sample type: Sample collection date: Sample accession date: Patient ID (MRN):	Saliva 18-MAR-2022 22-MAR-2022	Report date: Invitae #: Clinical team:	01-APR-2022 RQ3234942 Janine Mash Lorraine Bonner, MD
Reason for testing Gamete donor			e st performed vitae Comprehensive Ca	urrier Screen witho	ut X-linked Disorders

- Primary Panel (CF, SMA)
- Add-on Comprehensive Carrier Screen without X-linked Disorders genes



RESULT: POSITIVE

This carrier test evaluated 268 gene(s) for genetic changes (variants) that are associated with an increased risk of having a child with a genetic condition. Knowledge of carrier status for one of these conditions may provide information that can be used to assist with family planning and/or preparation.

This test shows the presence of clinically significant genetic change(s) in this individual in the gene(s) indicated below. No other clinically significant changes were identified in the remaining genes evaluated with this test.

GENE	VARIANT(S)	INHERITANCE	PARTNER TESTING RECOMMENDED
PMM2	c.422G>A (p.Arg141His)	Autosomal recessive	Yes
COL7A1	c.4568del (p.Pro1523Hisfs*187)	Autosomal recessive	Yes
	PMM2	PMM2 c.422G>A (p.Arg141His)	PMM2 c.422G>A (p.Arg141His) Autosomal recessive

Next steps

- See the table above for recommendations regarding testing of this individual's reproductive partner.
- Even for genes that have a negative test result, there is always a small risk that an individual could still be a carrier. This is called "residual risk." See the table below for residual risks, which presumes a negative family history of the conditions listed.
- Discussion with a physician and/or genetic counselor is recommended to further review the implications of this test result and to understand these results in the context of any family history of a genetic condition.
- All patients, regardless of result, may wish to consider additional screening for hemoglobinopathies by complete blood count (CBC) and hemoglobin electrophoresis, if this has not already been completed.
- Individuals can register their tests at https://www.invitae.com/patients/ to access online results, educational resources, and next steps.





Clinical summary

RESULT: CARRIER

Congenital disorder of glycosylation type Ia

A single Pathogenic variant, c.422G>A (p.Arg141His), was identified in PMM2.

What is congenital disorder of glycosylation type Ia?


Congenital disorders of glycosylation (CDGs) are a group of conditions in which individuals have difficulty adding or removing a sugar group to make glycoproteins. This process, called "glycosylation," is a necessary step to modify proteins for their intended purpose. CDGs affect several body systems. CDG type Ia (CDG-Ia) is the most common CDG. Age of onset and severity of symptoms are variable. The most severe cases involve excess fluid accumulation in the body (fetal hydrops) and result in stillbirth or newborn death. Symptoms typically present during the first year of life and commonly include low muscle tone (hypotonia), inverted nipples, abnormal fat distribution, and unusual facial features (dysmorphism). Other symptoms may include poor growth (failure to thrive), abnormal brain structure (cerebellar atrophy), eyes that do not look in the same direction (strabismus), delayed mental and movement abilities (psychomotor delay), difficulty coordinating movements (ataxia), intellectual disability, liver disease, joint deformities (contractures), and, in females, impaired response to sex hormones (hypergonadotropic hypogonadism). In some cases, the condition affects the kidneys, heart, and endocrine and/or immune systems. Approximately 20% of affected infants do not survive the first year of life due to organ failure. Symptoms in affected adolescents and adults may include difficulty coordinating speech (dysarthria), strabismus, abnormal sideto-side and front-to-back curvature of the spine (kyphoscoliosis), pain and reduced sensation due to nerve damage, typically in the hands and feet (peripheral neuropathy), problems with blood clotting such as prolonged or excessive bleeding (coagulopathy) or a tendency to form abnormal clots in blood vessels (thrombosis), stroke-like episodes, retinitis pigmentosa (RP, a disease of the light-sensitive tissue that lines the back of the eye [retina] that causes progressive vision loss), and, in females, premature ovarian failure, which causes early menopause. Individuals with milder symptoms and late-onset disease have also been reported. Follow-up depends on each affected individual's specific situation, and discussion with a healthcare provider should be considered.

Next steps

Carrier testing for the reproductive partner is recommended.

(+) If your partner tests positive:

In autosomal recessive inheritance, an individual must have disease-causing genetic changes in each copy of the PMM2 gene to be affected. Carriers, who have a disease-causing genetic change in only one copy of the gene, typically do not have symptoms. When both reproductive partners are carriers of an autosomal recessive condition, there is a 25% chance for each child to have the condition.



If your partner tests negative:

A negative carrier test result reduces, but does not eliminate, the chance that a person may be a carrier. The risk that a person could still be a carrier, even after a negative test result, is called a residual risk. See the table below for your partner's hypothetical

residual risk after testing negative for congenital disorder of glycosylation type Ia. These values are provided only as a guide, are based on the detection rate for the condition as tested at Invitae, and assume a negative family history, the absence of symptoms, and vary based on the ethnic background of an individual. For genes associated with both dominant and recessive inheritance, the numbers provided apply to the recessive condition(s) associated with the gene.

DISORDER (INHERITANCE)	GENE	ETHNICITY	CARRIER FREQUENCY BEFORE SCREENING	CARRIER RESIDUAL RISK AFTER NEGATIVE RESULT
Congenital disorder of glycosylation type Ia (AR) NM_000303.2		Ashkenazi Jewish	1 in 61	1 in 6000
	PMM2	Caucasian	1 in 60	1 in 5900
		Pan-ethnic	1 in 190	1 in 18900





• RESULT: CARRIER

Dystrophic epidermolysis bullosa

A single Pathogenic variant, c.4568del (p.Pro1523Hisfs*187), was identified in COL7A1.

What is dystrophic epidermolysis bullosa?

Dystrophic epidermolysis bullosa is a condition that can be inherited in an autosomal recessive or autosomal dominant manner. To understand which condition a genetic change is associated with, a review of the entire report, including the variant details section, is recommended.

Please note that the COL7A1 variant identified in this individual is expected to be associated with autosomal recessive dystrophic epidermolysis bullosa.

Epidermolysis bullosa (EB) is a group of conditions that affect the skin. EB is caused by a defect in collagen, the protein that gives skin its strength and holds it together. Defects in collagen cause extremely fragile skin. Dystrophic epidermolysis bullosa (DEB) is a form of EB, and is primarily characterized by blistering and scarring of skin and mucous membranes following minor trauma. Symptoms and severity are quite variable. Individuals with autosomal recessive DEB (RDEB) typically have more severe symptoms compared to individuals with autosomal dominant DEB (DDEB). Infants are often born with blisters and areas of missing skin over much of the body. Blisters in the mouth and digestive tract make feeding difficult, which leads to chronic malnutrition and poor growth (failure to thrive). As the blisters heal, this causes extensive scarring of the arms, legs, hands and feet, leading to joint deformities that restrict movement (contractures) and the fusion of fingers or toes (pseudosyndactyly). Affected individuals also have high risk for an aggressive form of skin cancer called squamous cell carcinoma, as well as vision loss due to scarring of the clear covering at the front of the eye (cornea); non-skin-related findings are also possible. The constellation of symptoms of RDEB can be life-threatening. Prognosis depends on the severity of symptoms. Follow-up depends on each affected individual's specific situation, and discussion with a healthcare provider should be considered.

Next steps


Carrier testing for the reproductive partner is recommended.

(+) If your partner tests positive:

In autosomal recessive inheritance, an individual must have disease-causing genetic changes in each copy of the COL7A1 gene to be affected. Carriers, who have a disease-causing genetic change in only one copy of the gene, typically do not have symptoms. When both reproductive partners are carriers of an autosomal recessive condition, there is a 25% chance for each child to have the condition.

If your partner tests negative:

A negative carrier test result reduces, but does not eliminate, the chance that a person may be a carrier. The risk that a person could still be a carrier, even after a negative test result, is called a residual risk. See the table below for your partner's



hypothetical residual risk after testing negative for dystrophic epidermolysis bullosa. These values are provided only as a guide, are based on the detection rate for the condition as tested at Invitae, and assume a negative family history, the absence of symptoms, and vary based on the ethnic background of an individual. For genes associated with both dominant and recessive inheritance, the numbers provided apply to the recessive condition(s) associated with the gene.

DISORDER (INHERITANCE)	GENE	ETHNICITY	CARRIER FREQUENCY BEFORE SCREENING	CARRIER RESIDUAL RISK AFTER NEGATIVE RESULT
Dystrophic epidermolysis bullosa (AR) NM_000094.3	COL7A1	Pan-ethnic	1 in 370	1 in 12300





Results to note

Pseudodeficiency alleles

Benign changes, c.742G>A (p.Asp248Asn) and c.1685T>C (p.Ile562Thr), known to be pseudodeficiency alleles, identified in the GALC gene. Pseudodeficiency alleles are not known to be associated with disease, including Krabbe disease.

The presence of a pseudodeficiency allele does not impact this individual's risk to be a carrier. Individuals with pseudodeficiency alleles may exhibit false positive results on related biochemical tests, including newborn screening; however, pseudodeficiency alleles are not known to cause disease, including Krabbe disease. Carrier testing for the reproductive partner is not indicated based on this result.

Variant details

COL7A1, Exon 45, c.4568del (p.Pro1523Hisfs*187), heterozygous, PATHOGENIC

- This sequence change creates a premature translational stop signal (p.Pro1523Hisfs*187) in the COL7A1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in COL7A1 are known to be pathogenic (PMID: 16971478).
- This variant is present in population databases (rs778165989, gnomAD 0.07%).
- This premature translational stop signal has been observed in individual(s) with autosomal recessive dystrophic epidermolysis bullosa (PMID: 24213372).
- ClinVar contains an entry for this variant (Variation ID: 372334).
- For these reasons, this variant has been classified as Pathogenic.

PMM2, Exon 5, c.422G>A (p.Arg141His), heterozygous, PATHOGENIC

- This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 141 of the PMM2 protein (p.Arg141His).
- This variant is present in population databases (rs28936415, gnomAD 0.8%).
- This missense change has been observed in individual(s) with PMM2-CDG (PMID: 9497260, 11517108, 19357119, 21541725, 25355454). It is commonly reported in individuals of European ancestry (PMID: 9497260, 11517108, 19357119, 21541725, 25355454).
- ClinVar contains an entry for this variant (Variation ID: 7706).
- Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt PMM2 protein function.
- Experimental studies have shown that this missense change affects PMM2 function (PMID: 21541725, 26014514).
- For these reasons, this variant has been classified as Pathogenic.





Residual risk

This table displays residual risks after a negative result for each of the genes and corresponding disorders. The values provided assume a negative family history and the absence of symptoms for each disorder. For genes associated with both dominant and recessive inheritance, the numbers in this table apply to the recessive condition(s) associated with the gene, unless otherwise noted. Residual risk values are provided for disorders when carrier frequency is greater than 1 in 500. For disorders with carrier frequency equal to, or less than, 1 in 500, residual risk is considered to be reduced substantially. When provided, residual risk values are inferred from published carrier frequencies, and estimated detection rates are based on testing technologies used at Invitae. Residual risks are provided only as a guide for assessing approximate risk given a negative result; values will vary based on the ethnic background of an individual. For individuals of mixed ethnicity, it is recommended to use the highest residual risk estimate. For any genes marked with an asterisk*, refer to the Limitations section below for detailed coverage information. In the case of a sample-specific limitation, "N/A" indicates that a residual risk value could not be calculated. AR = autosomal recessive, XL = X-linked, AD = autosomal dominant.

DISORDER (INHERITANCE)	GENE	ETHNICITY	CARRIER FREQUENCY BEFORE SCREENING	CARRIER RESIDUAL RISK AFTER NEGATIVE RESULT
3-hydroxy-3-methylglutaryl-CoA lyase deficiency (AR)	HMGCL	Pan-ethnic	≤1 in 500	Reduced
NM_000191.2	HMGCL	Portuguese	1 in 160	1 in 15900
ABCB11-related conditions (AR) NM_003742.2	ABCB11	Pan-ethnic	1 in 100	1 in 9900
ABCC8-related conditions (AR)		Ashkenazi Jewish	1 in 52	1 in 5100
NM_000352.4 When the mother is a noncarrier, but the father is a		Finnish	1 in 100	1 in 9900
carrier, there is a residual risk for focal disease (1 in 540 for the Ashkenazi Jewish population; undetermined in other ethnic groups)	ABCC8	Pan-ethnic	1 in 177	1 in 17600
Abetalipoproteinemia (AR)	MTTP	Ashkenazi Jewish	1 in 131	1 in 13000
NM_000253.3	WITTP	Pan-ethnic	≤1 in 500	Reduced
Achromatopsia (CNGB3-related) (AR) NM_019098.4	CNGB3	Pan-ethnic	1 in 93	1 in 9200
ACOX1-related conditions (AR) NM_004035.6	ACOX1	Pan-ethnic	≤1 in 500	Reduced
Acrodermatitis enteropathica (AR) NM_130849.3	SLC39A4	Pan-ethnic	1 in 354	1 in 35300
Adenosine deaminase deficiency (AR) NM_000022.2	ADA	Pan-ethnic	1 in 224	1 in 2788
Aicardi-Goutieres syndrome 5 (AR) NM_015474.3	SAMHD1	Pan-ethnic	≤1 in 500	Reduced
Aldosterone synthase deficiency (AR)	CYP11B2	Pan-ethnic	≤1 in 500	Reduced
NM_000498.3	CIFIIBZ	Sephardic Jewish (Iranian)	1 in 30	1 in 2900
Alpha-mannosidosis (AR) NM_000528.3	MAN2B1	Pan-ethnic	1 in 354	1 in 35300
	HBA1/	African-American	1 in 30	1 in 291
Alpha-thalassemia (AR)		Asian	1 in 20	1 in 191
NM_000558.4, NM_000517.4	HBA2 *	Caucasian	≤1 in 500	Reduced
		Pan-ethnic	1 in 25	1 in 241
Algorithmum drama (COLAA2 related) (AD)		Ashkenazi Jewish	1 in 192	1 in 19100
Alport syndrome (COL4A3-related) (AR) NM_000091.4	COL4A3	Caucasian	1 in 284	1 in 28300
		Pan-ethnic	1 in 354	1 in 35300
Alport syndrome (COL4A4-related) (AR) NM_000092.4	COL4A4	Pan-ethnic	1 in 353	1 in 35200
Alström syndrome (AR) NM_015120.4	ALMS1	Pan-ethnic	≤1 in 500	Reduced
Arginase deficiency (AR) NM_000045.3	ARG1	Pan-ethnic	1 in 274	1 in 27300
Argininosuccinate lyase deficiency (AR) NM_000048.3	ASL	Pan-ethnic	1 in 133	1 in 1321
Aromatase deficiency (AR) NM_031226.2	CYP19A1	Pan-ethnic	≤1 in 500	Reduced
Asparagine synthetase deficiency (AR) NM_133436.3	ASNS	Pan-ethnic	≤1 in 500	Reduced





DISORDER (INHERITANCE)	GENE	ETHNICITY	CARRIER FREQUENCY BEFORE SCREENING	CARRIER RESIDUAL RISK AFTER NEGATIVE RESULT
		Sephardic Jewish (Iranian)	1 in 80	1 in 7900
Aspartylglucosaminuria (AR)	AGA	Finnish	1 in 69	1 in 6800
NM_000027.3		Pan-ethnic	≤1 in 500	Reduced
Ataxia with vitamin E deficiency (AR)	TTPA	Italian	1 in 274	1 in 2731
NM_000370.3	TITA.	Pan-ethnic	≤1 in 500	Reduced
ATM-related conditions (AR)	ATM	Pan-ethnic	1 in 100	1 in 9900
NM_000051.3	710	Sephardic Jewish	1 in 69	1 in 6800
		Finnish	1 in 79	1 in 7800
Autoimmune polyendocrinopathy with candidiasis and	AIRE	Pan-ethnic	1 in 150	1 in 14900
ectodermal dysplasia (AR) NM_000383.3	AIRE	Sardinian	1 in 60	1 in 5900
		Sephardic Jewish (Iranian)	1 in 48	1 in 4700
Autosomal recessive congenital ichthyosis		Norwegian	1 in 151	1 in 3000
(TGM1-related) (AR) NM_000359.2	TGM1	Pan-ethnic	1 in 224	1 in 4460
Autosomal recessive spastic ataxia of Charlevoix- Saguenay (AR)	SACS	French Canadian (Saguenay-Lac-St- Jean)	1 in 21	1 in 2000
NM_014363.5		Pan-ethnic	≤1 in 500	Reduced
Bardet-Biedl syndrome (BBS10-related) (AR) NM_024685.3	BBS10	Pan-ethnic	1 in 354	1 in 35300
Bardet-Biedl syndrome (BBS12-related) (AR) NM_152618.2	BBS12	Pan-ethnic	1 in 708	Reduced
BBS1-related conditions (AR)		Faroese	1 in 30	1 in 2900
NM_024649.4	BBS1	Pan-ethnic	1 in 330	1 in 32900
BBS2-related conditions (AR)		Ashkenazi Jewish	1 in 140	1 in 13900
NM_031885.3	BBS2	Pan-ethnic	1 in 560	Reduced
		Caucasian	1 in 407	1 in 40600
BCS1L-related conditions (AR)	BCS1L	Finnish	1 in 108	1 in 10700
NM_004328.4		Pan-ethnic	≤1 in 500	Reduced
Beta-ketothiolase deficiency (AR)		Caucasian	1 in 354	1 in 35300
NM_000019.3	ACAT1	Pan-ethnic	≤1 in 500	Reduced
Biopterin-deficient hyperphenylalaninemia (PTS-related)		Chinese	1 in 122	1 in 12100
(AR) (AR) (AR) (AR) (AR) (AR) (AR) (AR)	PTS	Pan-ethnic	1 in 433	1 in 43200
Bloom syndrome (AR)	BLM	Ashkenazi Jewish	1 in 100	1 in 9900
NM_000057.3	BLIVI	Pan-ethnic	≤1 in 500	Reduced
BSND-related conditions (AR) NM_057176.2	BSND	Pan-ethnic	≤1 in 500	Reduced
Canavan disease (AR)	4604	Ashkenazi Jewish	1 in 57	1 in 5600
NM_000049.2	ASPA	Pan-ethnic	1 in 159	1 in 15800
Carbamoyl phosphate synthetase I deficiency (AR) NM_001875.4	CPS1	Pan-ethnic	≤1 in 500	Reduced
Carnitine palmitoyltransferase I deficiency (AR)	CDT1	Hutterite	1 in 16	1 in 1500
NM_001876.3	CPT1A	Pan-ethnic	≤1 in 500	Reduced
Carnitine palmitoyltransferase II deficiency (AR)		Ashkenazi Jewish	1 in 45	1 in 4400
NM_000098.2	CPT2	Pan-ethnic	1 in 182	1 in 18100
Carpenter syndrome (RAB23-related) (AR) NM_183227.2	RAB23	Pan-ethnic	≤1 in 500	Reduced
Cartilage-hair hypoplasia-anauxetic dysplasia spectrum		Amish	1 in 10	1 in 900
disorders (AR)	RMRP	Finnish	1 in 76	1 in 7500
NR_003051.3		Pan-ethnic	≤1 in 500	Reduced
CDH23-related conditions (AR) NM_022124.5	CDH23	Pan-ethnic	1 in 202	1 in 4020
CEP290-related conditions (AR) NM_025114.3	CEP290	Pan-ethnic	1 in 185	1 in 18400
Cerebrotendinous xanthomatosis (AR)	0)(0.5.1.1.1	Pan-ethnic	1 in 112	1 in 5550
NM_000784.3	CYP27A1	Sephardic Jewish	1 in 76	1 in 3750
CERKL-related conditions (AR)		Pan-ethnic	1 in 137	1 in 13600
NM_001030311.2	CERKL	Sephardic Jewish	1 in 24	1 in 2300





DISORDER (INHERITANCE)	GENE	ETHNICITY	CARRIER FREQUENCY BEFORE SCREENING	CARRIER RESIDUAL RISK AFTER NEGATIVE RESULT
		African-American - classic CF	1 in 61	1 in 6000
		Ashkenazi Jewish - classic CF	1 in 29	1 in 2800
CFTR-related conditions (AR)		Asian - classic CF	1 in 88	1 in 8700
NM_000492.3	CFTR	Caucasian - classic CF	1 in 28	1 in 2700
		Pan-ethnic - classic CF	1 in 45	1 in 4400
		Pan-ethnic - classic CF and CFTR- related disorders	1 in 9	1 in 800
Charcot-Marie-Tooth disease type 4D (AR) NM 006096.3	NDRG1	Pan-ethnic	≤1 in 500	Reduced
		Roma	1 in 22	1 in 2100
Chorea-acanthocytosis (AR) NM_033305.2	VPS13A *	Pan-ethnic	≤1 in 500	Reduced
Chronic granulomatous disease (CYBA-related) (AR)	СҮВА	Pan-ethnic	≤1 in 500	Reduced
NM_000101.3	CIDA	Sephardic Jewish (Moroccan)	1 in 13	1 in 1200
		Chinese	1 in 65	1 in 6400
		Japanese	1 in 65	1 in 6400
Citrin deficiency (AR)	SLC25A13	Korean	1 in 112	1 in 11100
NM_014251.2		Pan-ethnic	1 in 313	1 in 31200
		Southern Chinese and Taiwanese	1 in 48	1 in 4700
Citrullinemia type 1 (AR)	ASS1	Pan-ethnic	1 in 120	1 in 2975
NM_000050.4 CLN3-related conditions (AR)			1	
NM_001042432.1	CLN3	Pan-ethnic	1 in 230	1 in 22900
CLRN1-related conditions (AR)	CLRN1	Ashkenazi Jewish	1 in 120	1 in 11900
NM_174878.2 Cobalamin C deficiency (AR)		Pan-ethnic	1 in 533	Reduced
NM_015506.2	MMACHC	Pan-ethnic	1 in 123	1 in 12200
Cobalamin D deficiency (AR) NM_015702.2	MMADHC *	Pan-ethnic	≤1 in 500	Reduced
Cockayne syndrome A (AR) NM_000082.3	ERCC8	Pan-ethnic	1 in 514	Reduced
Cockayne syndrome B (AR) NM_000124.3	ERCC6	Pan-ethnic	1 in 377	1 in 37600
Cohen syndrome (AR)	V/DC13D	Amish (Ohio)	1 in 12	1 in 1100
NM_017890.4	VPS13B	Pan-ethnic	≤1 in 500	Reduced
Combined malonic and methylmalonic aciduria (AR) NM_174917.4	ACSF3	Pan-ethnic	1 in 87	1 in 8600
Combined oxidative phosphorylation deficiency 1 (AR) NM_024996.5	GFM1	Pan-ethnic	≤1 in 500	Reduced
Combined oxidative phosphorylation deficiency 3 (AR)		Finnish	1 in 80	1 in 1129
NM_001172696.1	TSFM *	Pan-ethnic	≤1 in 500	Reduced
Combined pituitary hormone deficiency (LHX3-related) (AR) NM_014564.4	LHX3	Pan-ethnic	≤1 in 500	Reduced
Combined pituitary hormone deficiency (PROP1-related) (AR) NM_006261.4	PROP1	Pan-ethnic	1 in 45	1 in 2200
Congenital adrenal hyperplasia due to 3-beta- hydroxysteroid dehydrogenase deficiency (AR) NM_000198.3	HSD3B2	Pan-ethnic	≤1 in 500	Reduced
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency (AR) NM_000500.7	CYP21A2 *	Pan-ethnic	1 in 61	1 in 751
Congenital disorder of glycosylation (SLC35A3-related)		Ashkenazi Jewish	1 in 469	1 in 46800
(AR) NM_012243.2	SLC35A3	Pan-ethnic	≤1 in 500	Reduced
Congenital disorder of glycosylation type Ib (AR) NM_002435.2	MPI	Pan-ethnic	≤1 in 500	Reduced
Congenital disorder of glycosylation type Ic (AR) NM_013339.3	ALG6 *	Pan-ethnic	≤1 in 500	Reduced
Congenital insensitivity to pain with anhidrosis (AR) NM_001012331.1	NTRK1	Pan-ethnic	≤1 in 500	Reduced





DISORDER (INHERITANCE)	GENE	ETHNICITY	CARRIER FREQUENCY BEFORE SCREENING	CARRIER RESIDUAL RISK AFTER NEGATIVE RESULT
Congenital myasthenic syndrome (CHRNE-related)		European Roma	1 in 25	1 in 2400
(AR) NM_000080.3	CHRNE	Pan-ethnic	1 in 200	1 in 19900
		Finnish	1 in 46	1 in 4500
Congenital nephrotic syndrome type 1 (AR) NM_004646.3	NPHS1	Old Order Mennonite	1 in 12	1 in 1100
NWI_004040.5		Pan-ethnic	≤1 in 500	Reduced
Congenital nephrotic syndrome type 2 (AR) NM_014625.3	NPHS2	Pan-ethnic	≤1 in 500	Reduced
Corneal dystrophy and perceptive deafness (AR) NM_032034.3	SLC4A11	Pan-ethnic	≤1 in 500	Reduced
CRB1-related conditions (AR) NM_201253.2	CRB1	Pan-ethnic	1 in 112	1 in 11100
CYP11B1-related conditions (AR)	CYP11B1	Pan-ethnic	1 in 194	1 in 19300
NM_000497.3	СППВГ	Sephardic Jewish (Moroccan)	1 in 40	1 in 3900
CYP17A1-related conditions (AR) NM_000102.3	CYP17A1	Pan-ethnic	≤1 in 500	Reduced
Cystinosis (AR)	CTNS	French Canadian (Saguenay-Lac-St- Jean)	1 in 39	1 in 3800
NM_004937.2	CINS	Pan-ethnic	1 in 158	1 in 15700
		Sephardic Jewish (Moroccan)	1 in 100	1 in 9900
DHDDS-related conditions (AR)	DHDDS	Ashkenazi Jewish	1 in 117	1 in 11600
NM_024887.3	BHBBB	Pan-ethnic	≤1 in 500	Reduced
Dihydrolipoamide dehydrogenase deficiency (AR)	DLD	Ashkenazi Jewish	1 in 107	1 in 5300
NM_000108.4	010	Pan-ethnic	≤1 in 500	Reduced
Distal renal tubular acidosis with deafness (ATP6V1B1-related) (AR) NM_001692.3		Pan-ethnic	≤1 in 500	Reduced
	ATP6V1B1	Sephardic Jewish	1 in 140	1 in 13900
DYSF-related conditions (AR) NM_003494.3	DYSF	Pan-ethnic	1 in 311	1 in 31000
		Sephardic Jewish (Libyan)	1 in 10	1 in 900
Dyskeratosis congenita spectrum disorders		Ashkenazi Jewish	1 in 222	1 in 22100
(RTEL1-related) (AR) NM_001283009.1	RTEL1	Pan-ethnic	≤1 in 500	Reduced
Ehlers-Danlos syndrome, dermatosparaxis type (AR)		Ashkenazi Jewish	1 in 187	1 in 18600
NM_014244.4	ADAMTS2	Pan-ethnic	≤1 in 500	Reduced
Ellis-van Creveld syndrome (EVC-related) (AR)	EVC	Amish	1 in 8	1 in 700
NM_153717.2	EVC	Pan-ethnic	1 in 220	1 in 21900
Ethylmalonic encephalopathy (AR) NM_014297.3	ETHE1	Pan-ethnic	≤1 in 500	Reduced
EVC2-related conditions (AR) NM_147127.4	EVC2	Pan-ethnic	1 in 199	1 in 19800
Familial chylomicronemia syndrome (AR)	LPL	French Canadian (Saguenay-Lac-St- Jean)	1 in 46	1 in 4500
NM_000237.2		Pan-ethnic	≤1 in 500	Reduced
Familial dysautonomia (AR)	ELP1	Ashkenazi Jewish	1 in 36	1 in 3500
NM_003640.3	ELPT	Pan-ethnic	≤1 in 500	Reduced
		Afrikaner	1 in 72	1 in 7100
Familial hypercholesterolemia (LDLR-related) (AD)		Ashkenazi Jewish	1 in 69	1 in 6800
NM_000527.4	LDLR	French Canadian	1 in 270	1 in 26900
		Pan-ethnic	1 in 250	1 in 24900
Familial hypercholesterolemia (LDLRAP1-related) (AR)	LDLRAP1	Pan-ethnic	≤1 in 500	Reduced
NM_015627.2	LULKAPI	Sardinian	1 in 143	1 in 14200
		Afrikaner	1 in 83	1 in 8200
Fanconi anemia type A (AR)	FANCA	Pan-ethnic	1 in 345	1 in 34400
NM_000135.2	IANCA	Sephardic Jewish	1 in 133	1 in 13200
		Spanish Roma	1 in 64	1 in 6300
Fanconi anemia type C (AR)	EANICO	Ashkenazi Jewish	1 in 89	1 in 8800
NM_000136.2	FANCC	Pan-ethnic	1 in 417	1 in 41600
Fanconi anemia type G (AR)	EANICO	African-American	1 in 100	1 in 9900
NM_004629.1	FANCG	Pan-ethnic	≤1 in 500	Reduced





DISORDER (INHERITANCE)	GENE	ETHNICITY	CARRIER FREQUENCY BEFORE SCREENING	CARRIER RESIDUAL RISK AFTER NEGATIVE RESULT
FH-related conditions (AR) NM_000143.3	FH	Pan-ethnic	≤1 in 500	Reduced
Galactokinase deficiency galactosemia (AR)	GALK1	Pan-ethnic	1 in 122	1 in 12100
NM_000154.1	GAERT	Roma	1 in 47	1 in 4600
		African-American	1 in 87	1 in 8600
Galactosemia (GALT-related) (AR) NM_000155.3	GALT	Ashkenazi Jewish	1 in 156	1 in 15500
	GALI	Irish Traveller	1 in 11	1 in 1000
		Pan-ethnic	1 in 100	1 in 9900
GBA-related conditions including Gaucher disease (AR)	GBA *	Ashkenazi Jewish	1 in 15	1 in 234
NM_001005741.2	OBA "	Pan-ethnic	1 in 158	1 in 561
GBE1-related conditions (AR)	GBE1	Ashkenazi Jewish	1 in 68	1 in 6700
NM_000158.3	GBEI	Pan-ethnic	1 in 387	1 in 38600
Gitelman syndrome (AR) NM_000339.2	SLC12A3	Pan-ethnic	1 in 100	1 in 9900
		Ashkenazi Jewish	1 in 13	1 in 1200
GJB2-related conditions (AR) NM_004004.5	GJB2	Pan-ethnic	1 in 50	1 in 4900
INIVI_004004.3		Thai	1 in 9	1 in 800
		Pan-ethnic	1 in 158	1 in 15700
GLB1-related conditions (AR) NM_000404.2	GLB1	Roma	1 in 50	1 in 4900
NW_000404.2		South Brazilian	1 in 58	1 in 5700
GLE1-related conditions (AR)		Finnish	1 in 100	1 in 9900
NM_001003722.1	GLE1	Pan-ethnic	≤1 in 500	Reduced
		Amish	1 in 9	1 in 800
Glutaric acidemia type I (AR)	GCDH	Oji-Cree First Nations	1 in 9	1 in 800
NM_000159.3	CODI	Pan-ethnic	1 in 87	1 in 8600
Glutaric acidemia type IIA (AR) NM_000126.3	ETFA	Pan-ethnic	≤1 in 500	Reduced
Glutaric acidemia type IIC (AR)		Asian	1 in 87	1 in 8600
NM_004453.3	ETFDH	Pan-ethnic	1 in 250	1 in 24900
Glycine encephalopathy (AMT-related) (AR)		Finnish	1 in 142	1 in 14100
NM 000481.3	AMT	Pan-ethnic	1 in 325	1 in 32400
		Caucasian	1 in 141	1 in 14000
Glycine encephalopathy (GLDC-related) (AR) NM 000170.2	GLDC	Pan-ethnic	1 in 165	1 in 16400
		Ashkenazi Jewish	1 in 71	1 in 1400
Glycogen storage disease type Ia (AR) NM_000151.3	G6PC	Pan-ethnic	1 in 177	1 in 3520
		African-American	1 in 60	1 in 5900
		Ashkenazi Jewish	1 in 58	1 in 5500
Glycogen storage disease type II (Pompe disease) (AR) NM 000152.3	GAA	Asikenazi jewish	1 in 112	1 in 11100
1111_000152.5	-	Pan-ethnic	1 in 100	1 in 9900
		Faroese	1 in 28	1 in 540
Glycogen storage disease type III (AR)	AGL	Pan-ethnic	1 in 28	1 in 3160
NM_000642.2	AGL			
		Sephardic Jewish (Moroccan) Caucasian	1 in 34	1 in 660
Glycogen storage disease type V (AR)	DYCM		1 in 158	1 in 15700
NM_005609.3	PYGM	Pan-ethnic	1 in 171	1 in 17000
		Sephardic Jewish (Kurdish)	1 in 84	1 in 8300
Glycogen storage disease type VII (AR) NM_000289.5	PFKM	Ashkenazi Jewish Pan-ethnic	1 in 250 ≤1 in 500	1 in 24900 Reduced
		Pan-ethnic	≤1 in 500 1 in 179	1 in 17800
GNE-related conditions (AR) NM_001128227.2	GNE			
		Sephardic Jewish (Iranian)	1 in 10	1 in 900
GNPTAB-related conditions (AR) NM_024312.4	GNPTAB	Irish Traveller	1 in 15	1 in 1400
		Pan-ethnic	1 in 200	1 in 19900
Guanidinoacetate methyltransferase deficiency (AR)	GAMT	Pan-ethnic	≤1 in 500	Reduced
NM_000156.5		Portuguese	1 in 125	1 in 12400
Gyrate atrophy of the choroid and retina (AR)		Finnish	1 in 126	1 in 12500
NM_000274.3	OAT *	Pan-ethnic	≤1 in 500	Reduced
		Sephardic Jewish	1 in 177	1 in 17600





DISORDER (INHERITANCE)	GENE	ETHNICITY	CARRIER FREQUENCY BEFORE SCREENING	CARRIER RESIDUAL RISK AFTER NEGATIVE RESULT
HADHA-related conditions (AR)		Caucasian	1 in 250	1 in 24900
NM_000182.4	HADHA	Finnish	1 in 125	1 in 12400
		Pan-ethnic	1 in 350	1 in 34900
		African-American	1 in 8	1 in 700
		Asian	1 in 54	1 in 5300
HBB-related hemoglobinopathies (AR)	НВВ	Caucasian	1 in 373	1 in 37200
NM_000518.4	TIDD	Hispanic	1 in 17	1 in 1600
		Mediterranean	1 in 28	1 in 2700
		Pan-ethnic	1 in 49	1 in 4800
		African-American	1 in 226	1 in 22500
Hereditary fructose intolerance (AR) NM 000035.3	ALDOB	Middle Eastern	1 in 97	1 in 9600
1111_000055.5		Pan-ethnic	1 in 122	1 in 12100
Hereditary hemochromatosis type 2 (HJV-related) (AR) NM_213653.3	HJV	Pan-ethnic	≤1 in 500	Reduced
Hereditary hemochromatosis type 3 (AR) NM_003227.3	TFR2	Pan-ethnic	≤1 in 500	Reduced
Hermansky-Pudlak syndrome type 1 (AR)	HPS1	Pan-ethnic	≤1 in 500	Reduced
NM_000195.4	HF21	Puerto Rican (Northwestern)	1 in 21	1 in 2000
		Ashkenazi Jewish	1 in 235	1 in 23400
Hermansky-Pudlak syndrome type 3 (AR) NM_032383.4	HPS3	Pan-ethnic	≤1 in 500	Reduced
NM_032383.4		Puerto Rican (Central)	1 in 63	1 in 6200
HGSNAT-related conditions (AR) NM_152419.2	HGSNAT	Pan-ethnic	≤1 in 500	Reduced
Holocarboxylase synthetase deficiency (AR) NM_000411.6		Faroese	1 in 20	1 in 1900
	HLCS	Japanese	1 in 158	1 in 15700
		Pan-ethnic	1 in 224	1 in 22300
Homocystinuria due to cobalamin E deficiency (AR) NM_002454.2	MTRR	Pan-ethnic	≤1 in 500	Reduced
Homocystinuria due to cystathionine beta-synthase		Norwegian	1 in 40	1 in 3900
deficiency (AR)	CBS	Pan-ethnic	1 in 224	1 in 22300
NM_000071.2	605	Qatari	1 in 21	1 in 2000
Homocystinuria due to MTHFR deficiency (AR)		Pan-ethnic	≤1 in 500	Reduced
NM_005957.4	MTHFR *	Sephardic Jewish (Bukharian)	1 in 39	1 in 3800
HSD17B4-related conditions (AR) NM_000414.3	HSD17B4	Pan-ethnic	1 in 158	1 in 15700
Hydrolethalus syndrome type 1 (AR)		Finnish	1 in 40	1 in 3900
NM_145014.2	HYLS1	Pan-ethnic	≤1 in 500	Reduced
Hyperornithinemia-hyperammonemia-homocitrullinuria		Metis (Saskatchewan)	1 in 19	1 in 1800
syndrome (AR) NM_014252.3	SLC25A15	Pan-ethnic	≤1 in 500	Reduced
Hypophosphatasia (AR)		Mennonite	1 in 25	1 in 480
NM_000478.5	ALPL	Pan-ethnic	1 in 150	1 in 2980
Isovaleric acidemia (AR) NM_002225.3	IVD	Pan-ethnic	1 in 250	1 in 24900
Joubert syndrome and related disorders (MKS1-related)		Finnish	1 in 47	1 in 920
(AR) NM_017777.3	MKS1	Pan-ethnic	1 in 260	1 in 5180
Joubert syndrome and related disorders (RPGRIP1L- related) (AR) NM_015272.2	RPGRIP1L *	Pan-ethnic	1 in 259	1 in 5160
Joubert syndrome and related disorders		Ashkenazi Jewish	1 in 92	1 in 9100
(TMEM216-related) (AR) NM_001173990.2	TMEM216	Pan-ethnic	≤1 in 500	Reduced
Junctional epidermolysis bullosa (LAMC2-related) (AR) NM_005562.2	LAMC2	Pan-ethnic	≤1 in 500	Reduced
KCNJ11-related conditions (AR) NM_000525.3	KCNJ11	Pan-ethnic	≤1 in 500	Reduced
Krabbe disease (AR)	CALCH	Druze	1 in 6	1 in 500
NM_000153.3	GALC *	Pan-ethnic	1 in 158	1 in 15700





DISORDER (INHERITANCE)	GENE	ETHNICITY	CARRIER FREQUENCY BEFORE SCREENING	CARRIER RESIDUAL RISK AFTER NEGATIVE RESULT
LAMA2-related muscular dystrophy (AR) NM_000426.3	LAMA2	Pan-ethnic	1 in 87	1 in 8600
LAMA3-related conditions (AR) NM_000227.4	LAMA3	Pan-ethnic	≤1 in 500	Reduced
LAMB3-related conditions (AR) NM_000228.2	LAMB3	Pan-ethnic	1 in 317	1 in 31600
Leber congenital amaurosis 5 (AR) NM_181714.3	LCA5	Pan-ethnic	1 in 645	Reduced
Leukoencephalopathy with vanishing white matter (EIF2B5-related) (AR) NM_003907.2	EIF2B5	Pan-ethnic	≤1 in 500	Reduced
Limb-girdle muscular dystrophy (CAPN3-related) (AR) NM_000070.2	CAPN3	Pan-ethnic	1 in 134	1 in 13300
		Caucasian	1 in 571	Reduced
		Japanese	1 in 374	1 in 37300
Limb-girdle muscular dystrophy type 2C (AR) NM_000231.2	SGCG	Moroccan	1 in 250	1 in 24900
NM_000231.2		Pan-ethnic	≤1 in 500	Reduced
		Roma	1 in 59	1 in 5800
		Caucasian	1 in 286	1 in 28500
Limb-girdle muscular dystrophy type 2D (AR)	SGCA	Finnish	1 in 150	1 in 14900
NM_000023.2		Pan-ethnic	≤1 in 500	Reduced
Limb-girdle muscular dystrophy type 2E (AR)		Caucasian	1 in 404	1 in 5038
NM_000232.4	SGCB	Pan-ethnic	≤1 in 500	Reduced
Lipoid congenital adrenal hyperplasia (AR)		Korean	1 in 170	1 in 16900
NM_000349.2	STAR	Pan-ethnic	≤1 in 500	Reduced
		Finnish	1 in 120	1 in 2380
Lysinuric protein intolerance (AR)	SLC7A7	Japanese	1 in 120	1 in 2380
ŃM_001126106.2		Pan-ethnic	≤1 in 500	Reduced
		Caucasian	≤1 m 300	1 in 1850
Lysosomal acid lipase deficiency (AR)	LIPA	Pan-ethnic	1 in 359	1 in 5967
NM_000235.3	LIFA	Sephardic Jewish (Iranian)	1 in 33	1 in 534
Major histocompatibility complex class II deficiency (CIITA-related) (AR) NM 000246.3	CIITA	Pan-ethnic	≤1 in 500	Reduced
Maple syrup urine disease type 1A (AR)		Mennonite	1 in 10	1 in 900
NM_000709.3	BCKDHA	Pan-ethnic	1 in 373	1 in 37200
Maple syrup urine disease type 1B (AR)		Ashkenazi Jewish	1 in 97	1 in 9600
NM_183050.2	BCKDHB	Pan-ethnic	1 in 346	1 in 34500
Maple syrup urine disease type 2 (AR) NM_001918.3	DBT	Pan-ethnic	≤1 in 500	Reduced
Medium-chain acyl-CoA dehydrogenase deficiency (AR)		Northern European	1 in 40	1 in 3900
NM_000016.5	ACADM	Pan-ethnic	1 in 66	1 in 6500
Megalencephalic leukoencephalopathy with subcortical		Pan-ethnic	≤1 in 500	Reduced
cysts 1 (AR) NM_015166.3	MLC1	Sephardic Jewish (Libyan)	1 in 40	1 in 3900
		Navajo	1 in 40	1 in 780
Metachromatic leukodystrophy (ARSA-related) (AR) NM_000487.5	ARSA	Pan-ethnic	1 in 100	1 in 1980
NWI_000487.5		Sephardic Jewish	1 in 46	1 in 900
Methylmalonic acidemia (MMAA-related) (AR) NM_172250.2	ММАА	Pan-ethnic	1 in 316	1 in 10500
Methylmalonic acidemia (MMAB-related) (AR) NM_052845.3	ММАВ	Pan-ethnic	1 in 456	1 in 22750
Methylmalonic acidemia (MUT-related) (AR) NM_000255.3	MUT	Pan-ethnic	1 in 204	1 in 5075
MFSD8-related conditions (AR) NM_152778.2	MFSD8	Pan-ethnic	≤1 in 500	Reduced
Microcephaly, postnatal progressive, with seizures and		Pan-ethnic	≤1 in 500	Reduced
brain atrophy (AR) NM_004268.4	MED17	Sephardic Jewish	1 in 20	1 in 1900





DISORDER (INHERITANCE)	GENE	ETHNICITY	CARRIER FREQUENCY BEFORE SCREENING	CARRIER RESIDUAL RISK AFTER NEGATIVE RESULT
Mitochondrial complex I deficiency 9 (AR) NM_004553.4	NDUFS6	Ashkenazi Jewish	1 in 290	1 in 28900
		Caucasus Jewish	1 in 24	1 in 2300
		Pan-ethnic	≤1 in 500	Reduced
Mitochondrial complex I deficiency 16 (AR)	NDUFAF5	Ashkenazi Jewish	1 in 290	1 in 28900
NM_024120.4		Pan-ethnic	≤1 in 500	Reduced
Mitochondrial complex I deficiency 20/ACAD9 deficiency (AR) NM_014049.4	ACAD9	Pan-ethnic	≤1 in 500	Reduced
Mitochondrial complex IV deficiency / Leigh syndrome, French Canadian type (AR)	LRPPRC	French Canadian (Saguenay-Lac-St- Jean)	1 in 23	1 in 2200
NM_133259.3		Pan-ethnic	≤1 in 500	Reduced
Mitochondrial neurogastrointestinal encephalomyopathy (AR)	TYMP	Pan-ethnic	≤1 in 500	Reduced
NM_001953.4		Sephardic Jewish	1 in 158	1 in 15700
MPL-related conditions (AR)	MPL	Ashkenazi Jewish	1 in 57	1 in 5600
NM_005373.2	IVIF L	Pan-ethnic	≤1 in 500	Reduced
MPV17-related conditions (AR)	MPV17	Navajo	1 in 20	1 in 475
NM_002437.4		Pan-ethnic	≤1 in 500	Reduced
Mucolipidosis type III gamma (AR) NM_032520.4	GNPTG	Pan-ethnic	≤1 in 500	Reduced
Mucolipidosis type IV (AR)	MCOLN1	Ashkenazi Jewish	1 in 100	1 in 9900
NM_020533.2	WICOLINT	Pan-ethnic	≤1 in 500	Reduced
Mucopolysaccharidosis type I (AR) NM_000203.4	IDUA	Pan-ethnic	1 in 148	1 in 4900
		Northern European	1 in 173	1 in 17200
Mucopolysaccharidosis type IIIA (AR) NM_000199.3	SGSH	Pan-ethnic	1 in 215	1 in 21400
1111_000199.5		Taiwanese	≤1 in 500	Reduced
Mucopolysaccharidosis type IIIB (AR) NM_000263.3	NAGLU	Pan-ethnic	1 in 224	1 in 22300
Mucopolysaccharidosis type IIID (AR) NM_002076.3	GNS	Pan-ethnic	≤1 in 500	Reduced
Mucopolysaccharidosis type IX (AR) NM_153281.1	HYAL1	Pan-ethnic	≤1 in 500	Reduced
Mucopolysaccharidosis type VI (AR) NM_000046.3	ARSB	Pan-ethnic	1 in 250	1 in 24900
Multiple sulfatase deficiency (AR) NM_182760.3	SUMF1	Pan-ethnic	≤1 in 500	Reduced
Muscular dystrophy-dystroglycanopathy (FKRP-related)	FKRP	Norwegian	1 in 116	1 in 11500
(AR) NM_024301.4		Pan-ethnic	1 in 158	1 in 15700
Muscular dystrophy-dystroglycanopathy (FKTN-related)	FKTN	Ashkenazi Jewish	1 in 80	1 in 7900
(AR)		Japanese	1 in 188	1 in 18700
NM_001079802.1		Pan-ethnic	≤1 in 500	Reduced
MYO7A-related conditions (AR) NM_000260.3	MYO7A	Pan-ethnic	1 in 200	1 in 3980
Myopathy, lactic acidosis, and sideroblastic anemia 1 (AR) NM_025215.5	PUS1	Pan-ethnic	≤1 in 500	Reduced
N-acetylglutamate synthase deficiency (AR) NM_153006.2	NAGS	Pan-ethnic	≤1 in 500	Reduced
Nemaline myopathy 2 (AR) NM 001271208.1	NEB *	Ashkenazi Jewish	1 in 108	1 in 10700
Nephrogenic diabetes insipidus (AQP2-related) (AR)	AQP2	Pan-ethnic Pan-ethnic	1 in 158 1 in 1118	1 in 3140 Reduced
NM_000486.5	PPT1			
Neuronal ceroid lipofuscinosis type 1 (AR) NM_000310.3		Finnish	1 in 70	1 in 3450
		Pan-ethnic Newfoundland	1 in 199 1 in 53	1 in 9900 1 in 1734
Neuronal ceroid lipofuscinosis type 2 (AR) NM_000391.3	TPP1	Pan-ethnic	1 in 250	1 in 1734
Neuronal ceroid lipofuscinosis type 5 (AR)		Finnish	1 in 115	1 in 11400
NM_006493.2	CLN5	Pan-ethnic	≤1 in 500	Reduced





DISORDER (INHERITANCE)	GENE	ETHNICITY	CARRIER FREQUENCY BEFORE SCREENING	CARRIER RESIDUAL RISK AFTER NEGATIVE RESULT
Neuronal ceroid lipofuscinosis type 6 (AR) NM_017882.2	CLN6	Pan-ethnic	≤1 in 500	Reduced
Neuronal ceroid lipofuscinosis type 8 (AR)	CLN8	Finnish	1 in 135	1 in 13400
NM_018941.3		Pan-ethnic	≤1 in 500	Reduced
Niemann-Pick disease type C (NPC1-related) (AR) NM_000271.4	NPC1	Pan-ethnic	1 in 183	1 in 18200
Niemann-Pick disease type C (NPC2-related) (AR) NM_006432.3	NPC2	Pan-ethnic	1 in 871	Reduced
Niemann-Pick disease types A and B (AR)	SMPD1	Ashkenazi Jewish	1 in 90	1 in 1780
NM_000543.4	0.001 0.1	Pan-ethnic	1 in 250	1 in 4980
Nijmegen breakage syndrome (AR)	NBN *	Eastern European	1 in 155	1 in 15400
NM_002485.4		Pan-ethnic	≤1 in 500	Reduced
Nonsyndromic deafness (LOXHD1-related) (AR)	LOXHD1	Ashkenazi Jewish	1 in 180	1 in 17900
NM_144612.6	-	Pan-ethnic	≤1 in 500	Reduced
NR2E3-related conditions (AR) NM_014249.3	NR2E3	Pan-ethnic	≤1 in 500	Reduced
OPA3-related conditions (AR)	OPA3	Pan-ethnic	≤1 in 500	Reduced
NM_025136.3	01713	Sephardic Jewish (Iraqi)	1 in 10	1 in 900
Osteopetrosis (TCIRG1-related) (AR)		Ashkenazi Jewish	1 in 350	1 in 34900
NM_006019.3	TCIRG1	Chuvash	1 in 30	1 in 2900
		Pan-ethnic	1 in 317	1 in 31600
PCDH15-related conditions (AR)	PCDH15	Ashkenazi Jewish	1 in 78	1 in 7700
NM_033056.3		Pan-ethnic	1 in 400	1 in 39900
PEX7-related conditions (AR) NM_000288.3	PEX7	Pan-ethnic	1 in 157	1 in 15600
		African-American	1 in 111	1 in 11000
	РАН	Ashkenazi Jewish	1 in 225	1 in 22400
		East Asian	1 in 50	1 in 1225
Phenylalanine hydroxylase deficiency (AR)		Finnish	1 in 225	1 in 22400
NM_000277.1		Irish	1 in 33	1 in 3200
		Japanese	1 in 200	1 in 19900
		Pan-ethnic	1 in 58	1 in 5700
		Turkish	1 in 26	1 in 2500
Phosphoglycerate dehydrogenase deficiency (AR)	PHGDH	Ashkenazi Jewish	1 in 400	1 in 39900
NM_006623.3		Pan-ethnic	≤1 in 500	Reduced
Polycystic kidney disease (PKHD1-related) (AR) NM_138694.3	PKHD1	Pan-ethnic	1 in 70	1 in 6900
Polymicrogyria (ADGRG1-related) (AR) NM_005682.6	ADGRG1	Pan-ethnic	≤1 in 500	Reduced
POMGNT1-related conditions (AR)	POMONITI	Finnish	1 in 111	1 in 11000
NM_017739.3	POMGNT1	Pan-ethnic	≤1 in 500	Reduced
Pontocerebellar hypoplasia type 2D (AR)	SEPSECS	Pan-ethnic	≤1 in 500	Reduced
NM_016955.3		Sephardic Jewish (Moroccan and Iraqi)	1 in 43	1 in 4200
Pontocerebellar hypoplasia type 6 (AR) NM_020320.3	RARS2	Pan-ethnic	≤1 in 500	Reduced
	SLC22A5	Faroese	1 in 9	1 in 800
Primary carnitine deficiency (AR) NM_003060.3		Japanese	1 in 100	1 in 9900
		Pan-ethnic	1 in 71	1 in 7000
Primary ciliary dyskinesia (DNAH5-related) (AR) NM_001369.2	DNAH5	Pan-ethnic	1 in 109	1 in 10800
Primary ciliary dyskinesia (DNAI1-related) (AR) NM_012144.3	DNAI1	Pan-ethnic	1 in 250	1 in 24900
Primary ciliary dyskinesia (DNAI2-related) (AR)		Ashkenazi Jewish	1 in 200	1 in 19900
NM_023036.4	DNAI2	Pan-ethnic	1 in 354	1 in 35300
Primary hyperoxaluria type 1 (AR)	ACYT	Pan-ethnic	1 in 125	1 in 12400
NM_000030.2	AGXT	Pari-ethnic	1 in 135	1 in 13400





DISORDER (INHERITANCE)	GENE	ETHNICITY	CARRIER FREQUENCY BEFORE SCREENING	CARRIER RESIDUAL RISK AFTER NEGATIVE RESULT
Primary hyperoxaluria type 2 (AR) NM_012203.1	GRHPR	Pan-ethnic	≤1 in 500	Reduced
Primary hyperoxaluria type 3 (AR) NM_138413.3	HOGA1	Pan-ethnic	1 in 354	1 in 35300
Propionic acidemia (PCCA-related) (AR) NM_000282.3	PCCA	Arab	1 in 100	1 in 2475
		Pan-ethnic	1 in 224	1 in 5575
		Arab	1 in 100	1 in 9900
Propionic acidemia (PCCB-related) (AR) NM_000532.4	РССВ	Greenlandic Inuit	1 in 20	1 in 1900
NNI_000332.4		Pan-ethnic	1 in 224	1 in 22300
PSAP-related conditions (AR) NM_002778.3	PSAP	Pan-ethnic	≤1 in 500	Reduced
Pycnodysostosis (AR) NM_000396.3	СТЅК	Pan-ethnic	1 in 438	1 in 43700
Pyruvate carboxylase deficiency (AR)	PC	Algonquian Indian	1 in 10	1 in 180
NM_000920.3	TC I	Pan-ethnic	1 in 250	1 in 4980
Pyruvate dehydrogenase complex deficiency (PDHB- related) (AR) NM_000925.3	PDHB	Pan-ethnic	≤1 in 500	Reduced
RAPSN-related conditions (AR) NM_005055.4	RAPSN	Pan-ethnic	1 in 283	1 in 28200
RDH12-related conditions (AR) NM_152443.2	RDH12	Pan-ethnic	1 in 460	1 in 45900
Retinitis pigmentosa 25 (AR)	EYS	Pan-ethnic	1 in 129	1 in 12800
NM_001142800.1	2.0	Sephardic Jewish	1 in 42	1 in 4100
Retinitis pigmentosa 28 (AR)		Ashkenazi Jewish	1 in 214	1 in 21300
NM_001201543.1	FAM161A	Pan-ethnic	1 in 289	1 in 28800
		Sephardic Jewish	1 in 41	1 in 4000
Rhizomelic chondrodysplasia punctata type 3 (AR) NM_003659.3	AGPS	Pan-ethnic	≤1 in 500	Reduced
Roberts syndrome (AR) NM_001017420.2	ESCO2	Pan-ethnic	≤1 in 500	Reduced
RPE65-related conditions (AR)	RPE65	Pan-ethnic	1 in 228	1 in 22700
NM_000329.2		Sephardic Jewish	1 in 90	1 in 8900
Sandhoff disease (AR)	НЕХВ	Metis (Saskatchewan)	1 in 15	1 in 1400
NM_000521.3		Pan-ethnic	1 in 180	1 in 17900
Schimke immuno-osseous dysplasia (AR) NM_014140.3	SMARCAL1	Pan-ethnic	≤1 in 500	Reduced
Severe combined immunodeficiency due to DCLRE1C	DCLRE1C	Navajo and Apache	1 in 10	1 in 900
(Artemis) deficiency (AR) NM_001033855.2		Pan-ethnic	≤1 in 500	Reduced
Severe combined immunodeficiency due to RAG2 deficiency (AR) NM_000536.3	RAG2	Pan-ethnic	≤1 in 500	Reduced
Severe congenital neutropenia due to HAX1 deficiency (AR) NM_006118.3	HAX1	Pan-ethnic	≤1 in 500	Reduced
Severe congenital neutropenia due to VPS45 deficiency (AR) NM_007259.4	VPS45	Pan-ethnic	≤1 in 500	Reduced
Sialic acid storage diseases (AR)	SI CI 745	Finnish	1 in 100	1 in 9900
NM_012434.4	SLC17A5	Pan-ethnic	≤1 in 500	Reduced
Sjögren-Larsson syndrome (AR)	ALDH3A2	Pan-ethnic	≤1 in 500	Reduced
NM_000382.2		Swedish	1 in 250	1 in 24900
SLC12A6-related conditions (AR)	SLC12A6	French Canadian (Saguenay-Lac-St- Jean)	1 in 23	1 in 2200
NM_133647.1		Pan-ethnic	≤1 in 500	Reduced
SLC26A2-related conditions (AR)	SI COCAD	Finnish	1 in 75	1 in 1480
NM_000112.3	SLC26A2	Pan-ethnic	1 in 158	1 in 3140
SLC26A4-related conditions (AR)	SLCOCAA	Asian	1 in 74	1 in 7300
NM_000441.1	SLC26A4	Pan-ethnic	1 in 80	1 in 7900





DISORDER (INHERITANCE)	GENE	ETHNICITY	CARRIER FREQUENCY BEFORE SCREENING	CARRIER RESIDUAL RISK AFTER NEGATIVE RESULT
SLC37A4-related conditions (AR) NM_001164277.1	SLC37A4	Pan-ethnic	1 in 354	1 in 7060
Smith-Lemli-Opitz syndrome (AR) NM_001360.2	DHCR7	African-American	1 in 339	1 in 33800
		Ashkenazi Jewish	1 in 41	1 in 4000
		Hispanic	1 in 135	1 in 13400
		Northern European	1 in 50	1 in 4900
		Pan-ethnic	1 in 71	1 in 7000
		Sephardic Jewish	1 in 68	1 in 6700
		Southern European	1 in 83	1 in 8200
Spastic paraplegia type 15 (AR) NM_015346.3	ZFYVE26	Pan-ethnic	≤1 in 500	Reduced
Spastic paraplegia type 49 (AR)	TECPR2	Pan-ethnic	≤1 in 500	Reduced
NM_014844.3	TECHNZ	Sephardic Jewish - Bukharian	1 in 38	1 in 3700
Spinal muscular atrophy (AR)		African-American	1 in 59	1 in 342
NM_000344.3		Ashkenazi Jewish	1 in 62	1 in 1017
SMN1: 2 copies c.*3+80T>G not detected	SMN1 *	Asian	1 in 50	1 in 701
Carrier residual risks listed are for 2 copy SMN1 results.	0	Caucasian	1 in 45	1 in 880
Carrier residual risk for >2 copies are 5- to 10-fold		Hispanic	1 in 48	1 in 784
ower.		Pan-ethnic	1 in 49	1 in 800
Spondylocostal dysostosis (MESP2-related) (AR)	MESP2	Pan-ethnic	1 in 224	1 in 22300
NM_001039958.1	WIEST 2	Puerto Rican	1 in 55	1 in 5400
Steel syndrome (AR)	COL27A1 *	Pan-ethnic	≤1 in 500	Reduced
NM_032888.3 Stüve-Wiedemann syndrome (AR)		Puerto Rican	1 in 51	1 in 5000
NM_002310.5	LIFR	Pan-ethnic	≤1 in 500	Reduced
		Ashkenazi Jewish	1 in 27	1 in 2600
		Asian	1 in 126	1 in 12500
	HEXA	Caucasian	1 in 182	1 in 18100
Γay-Sachs disease (AR) NM_000520.4		French Canadian	1 in 27	1 in 2600
1111_000320.4		Irish	1 in 41	1 in 4000
		Pan-ethnic	1 in 250	1 in 24900
		Sephardic Jewish	1 in 125	1 in 12400
Fransient infantile liver failure (AR)	TRMU	Pan-ethnic	≤1 in 500	Reduced
NM_018006.4	TRIVIO	Sephardic Jewish (Yemenite)	1 in 34	1 in 3300
Tyrosine hydroxylase deficiency (AR)	TH	Caucasian	1 in 224	1 in 22300
NM_199292.2	10	Pan-ethnic	≤1 in 500	Reduced
		Ashkenazi Jewish	1 in 143	1 in 2840
Fyrosinemia type I (AR)	FAH *	French Canadian	1 in 66	1 in 1300
NM_000137.2		French Canadian (Saguenay-Lac-St- Jean)	1 in 16	1 in 300
		Pan-ethnic	1 in 125	1 in 2480
Гуrosinemia type II (AR) NM_000353.2	TAT	Pan-ethnic	1 in 250	1 in 24900
		French Canadian/Acadian	1 in 227	1 in 22600
USH1C-related conditions (AR) NM_005709.3	USH1C *	Pan-ethnic	1 in 353	1 in 3521
<u> </u>		Sephardic Jewish	1 in 125	1 in 1241
	USH2A	Caucasian	1 in 70	1 in 6900
USH2A-related conditions (AR)		Pan-ethnic	1 in 112	1 in 11100
NM_206933.2		Sephardic Jewish	1 in 36	1 in 3500
/ery long-chain acyl-CoA dehydrogenase deficiency (AR) NM_000018.3	ACADVL	Pan-ethnic	1 in 100	1 in 9900
VRK1-related conditions (AR)		Ashkenazi Jewish	1 in 225	1 in 22400
NM_003384.2	VRK1	Pan-ethnic	≤1 in 500	Reduced
VSX2-related conditions (AR)		Pan-ethnic	≤1 in 500	Reduced
NM_182894.2	VSX2	Sephardic Jewish	1 in 145	1 in 14400





Invitae #: RQ3234942

DISORDER (INHERITANCE)	GENE	ETHNICITY	CARRIER FREQUENCY BEFORE SCREENING	CARRIER RESIDUAL RISK AFTER NEGATIVE RESULT
Wilson disease (AR) NM_000053.3	АТР7В	Ashkenazi Jewish	1 in 67	1 in 3300
		Canary Islander	1 in 25	1 in 1200
		Pan-ethnic	1 in 90	1 in 4450
1111_000033.5		Sardinian	1 in 50	1 in 2450
		Sephardic Jewish	1 in 65	1 in 3200
WNT10A-related conditions (AR) NM_025216.2	WNT10A	Pan-ethnic	1 in 305	1 in 30400
Xeroderma pigmentosum complementation group A	ХРА	Japanese	1 in 100	1 in 9900
(AR) NM_000380.3		Pan-ethnic	1 in 1667	Reduced
Xeroderma pigmentosum complementation group C	ХРС	Pan-ethnic	1 in 763	Reduced
(AR) NM_004628.4		Tunisian	1 in 50	1 in 4900
Zellweger spectrum disorder (PEX1-related) (AR) NM_000466.2	PEX1	Pan-ethnic	1 in 144	1 in 14300
Zellweger spectrum disorder (PEX2-related) (AR)	PEX2	Ashkenazi Jewish	1 in 227	1 in 22600
NM_000318.2		Pan-ethnic	≤1 in 500	Reduced
Zellweger spectrum disorder (PEX6-related) (AR) NM_000287.3	PEX6	French Canadian	1 in 55	1 in 5400
		Pan-ethnic	1 in 294	1 in 29300
		Sephardic Jewish	1 in 18	1 in 1700
Zellweger spectrum disorder (PEX10-related) (AR) NM_153818.1	PEX10	Pan-ethnic	1 in 606	Reduced
Zellweger spectrum disorder (PEX12-related) (AR) NM_000286.2	PEX12	Pan-ethnic	1 in 409	1 in 40800

Methods

Genomic DNA obtained from the submitted sample is enriched for targeted regions using a hybridization-based protocol, and sequenced using Illumina technology. Unless otherwise indicated, all targeted regions are sequenced with ≥50x depth or are supplemented with additional analysis. Reads are aligned to a reference sequence (GRCh37), and sequence changes are identified and interpreted in the context of a single clinically relevant transcript, indicated below. Enrichment and analysis focus on the coding sequence of the indicated transcripts, 10bp of flanking intronic sequence, and other specific genomic regions demonstrated to be causative of disease at the time of assay design. Promoters, untranslated regions, and other non-coding regions are not otherwise interrogated. Exonic deletions and duplications are called using an in-house algorithm that determines copy number at each target by comparing the read depth for each target in the proband sequence with both mean read-depth and read-depth distribution, obtained from a set of clinical samples. Markers across the X and Y chromosomes are analyzed for quality control purposes and may detect deviations from the expected sex chromosome complement. Such deviations may be included in the report in accordance with internal guidelines. Invitae utilizes a classification methodology to identify next-generation sequencing (NGS)-detected variants that require orthogonal confirmation (Lincoln, et al. J Mol Diagn. 2019 Mar;21(2):318-329.). Pathogenic and Likely Pathogenic variants that do not meet the validated quality thresholds are confirmed. Confirmation technologies may include any of the following: Sanger sequencing, Pacific Biosciences SMRT sequencing, MLPA, MLPA-seq, Array CGH.Array CGH confirmation of NGS CNV calling performed by Invitae Corporation (1400 16th Street, San Francisco, CA 94103, #05D2040778). The following analyses are performed if relevant to the requisition. For GBA the reference genome has been modified to mask the sites of polymorphic paralog sequence variants (PSVs) in both the gene and pseudogene. For CYP21A2 and GBA, if one or more reportable variants, gene conversion, or fusion event is identified via our NGS pipeline (see Limitations), these variants are confirmed by PacBio sequencing of an amplicon generated by long-range PCR and subsequent short-range PCR. In some cases, it may not be possible to disambiguate between the gene and pseudogene. For HBA1/2, the reference genome has been modified to force some sequencing reads derived from HBA1 to align to HBA2, and variant calling algorithms are modified to support an expectation of 4 alleles in these regions. HBA1/2 copy number calling is performed by a custom hypothesis testing algorithm which generates diplotype calls. If sequence data for a sample does not support a unique high confidence match from among hypotheses tested, that sample is flagged for manual review. Copy number variation is only reported for coding sequence of HBA1 and HBA2 and the HS-40 region. This assay does not distinguish among the -α3.7 subtypes, and all -α3.7 variants are called as HBA1 deletions. This assay may not detect overlapping copy gain and copy loss events when the breakpoints of those events are similar. For FMR1, triplet repeats are detected by PCR with fluorescently labeled primers followed by capillary electrophoresis. Reference ranges: Normal: <45 CGG repeats, intermediate: 45-54 CGG repeats, premutation: 55-200 CGG repeats, full mutation:



>200 CGG repeats. For alleles with 55-90 triplet repeats, the region surrounding the FMR1 repeat is amplified by PCR. The PCR amplicons are then processed through PacBio SMRTBell library prep and sequenced using PacBio long read technology. The number of AGG interruptions within the 55-90 triplet repeat is read directly from the resulting DNA sequences. Technical component of confirmatory sequencing is performed by Invitae Corporation (1400 16th Street, San Francisco, CA 94103, #05D2040778).

The following transcripts were used in this analysis. If more than one transcript is listed for a single gene, variants were reported using the first transcript listed unless otherwise indicated in the report: ABCB11 (NM_003742.2), ABCC8 (NM_000352.4), ACAD9 (NM_014049.4), ACADM (NM_000016.5), ACADVL (NM_000018.3), ACAT1 (NM_000019.3), ACOX1 (NM_004035.6), ACSF3 (NM_174917.4), ADA (NM_000022.2), ADAMTS2 (NM_014244.4), ADGRG1 (NM_005682.6), AGA (NM_000027.3), AGL (NM_000642.2), AGPS (NM_003659.3), AGXT (NM_000030.2), AIRE (NM_000383.3), ALDH3A2 (NM_000382.2), ALDOB (NM_000035.3), ALG6 (NM_013339.3), ALMS1 (NM_015120.4), ALPL (NM_000478.5), AMT (NM_000481.3), AQP2 (NM_000486.5), ARG1 (NM_000045.3), ARSA (NM_000487.5), ARSB (NM_000046.3), ASL (NM_000048.3), ASNS (NM_133436.3), ASPA (NM_000049.2), ASS1 (NM_000050.4), ATM (NM_000051.3), ATP6V1B1 (NM_001692.3), ATP7B (NM_000053.3), BBS1 (NM_024649.4), BBS10 (NM_024685.3), BBS12 (NM_152618.2), BBS2 (NM_031885.3), BCKDHA (NM_000709.3), BCKDHB (NM_183050.2), BCS1L (NM_004328.4), BLM (NM_000057.3), BSND (NM_057176.2), CAPN3 (NM_000070.2), CBS (NM_000071.2), CDH23 (NM_022124.5), CEP290 (NM_025114.3), CERKL (NM_001030311.2), CFTR (NM_000492.3), CHRNE (NM_000080.3), CIITA (NM_000246.3), CLN3 (NM_001042432.1), CLN5 (NM_006493.2), CLN6 (NM_017882.2), CLN8 (NM_018941.3), CLRN1 (NM_174878.2), CNGB3 (NM_019098.4), COL27A1 (NM_032888.3), COL4A3 (NM_000091.4), COL4A4 (NM_000092.4), COL7A1 (NM_000094.3), CPS1 (NM_001875.4), CPT1A (NM_001876.3), CPT2 (NM_000098.2), CRB1 (NM_201253.2), CTNS (NM_004937.2), CTSK (NM_000396.3), CYBA (NM_000101.3), CYP11B1 (NM_000497.3), CYP11B2 (NM_000498.3), CYP17A1 (NM_000102.3), CYP19A1 (NM_031226.2), CYP21A2 (NM_000500.7), CYP27A1 (NM_000784.3), DBT (NM_001918.3), DCLRE1C (NM_001033855.2), DHCR7 (NM_001360.2), DHDDS (NM_024887.3), DLD (NM_000108.4), DNAH5 (NM_001369.2), DNAI1 (NM_012144.3), DNAI2 (NM_023036.4), DYSF (NM_003494.3), EIF2B5 (NM_003907.2), ELP1 (NM_003640.3), ERCC6 (NM_000124.3), ERCC8 (NM_000082.3), ESCO2 (NM_001017420.2), ETFA (NM_000126.3), ETFDH (NM_004453.3), ETHE1 (NM_014297.3), EVC (NM_153717.2), EVC2 (NM_147127.4), EVS (NM_001142800.1), FAH (NM_000137.2), FAM161A (NM_001201543.1), FANCA (NM_000135.2), FANCC (NM_000136.2), FANCG (NM_004629.1), FH (NM_000143.3), FKRP (NM_024301.4), FKTN (NM_001079802.1), G6PC (NM_000151.3), GAA (NM_000152.3), GALC (NM_000153.3), GALK1 (NM_000154.1), GALT (NM_000155.3), GAMT (NM_000156.5), GBA (NM_001005741.2), GBE1 (NM_000158.3), GCDH (NM_000159.3), GFM1 (NM_024996.5), GJB2 (NM_004004.5), GLB1 (NM_000404.2), GLDC (NM_000170.2), GLE1 (NM_001003722.1), GNE (NM_001128227.2), GNPTAB (NM_024312.4), GNPTG (NM_032520.4), GNS (NM_002076.3), GRHPR (NM_012203.1), HADHA (NM_000182.4), HAX1 (NM_006118.3), HBA1 (NM_000558.4), HBA2 (NM_000517.4), HBB (NM_000518.4), HEXA (NM_000520.4), HEXB (NM_000521.3), HGSNAT (NM_152419.2), HJV (NM_213653.3), HLCS (NM_000411.6), HMGCL (NM_000191.2), HOGA1 (NM_138413.3), HPS1 (NM_000195.4), HPS3 (NM_032383.4), HSD17B4 (NM_000414.3), HSD3B2 (NM_000198.3), HYAL1 (NM_153281.1), HYLS1 (NM_145014.2), IDUA (NM_000203.4), IVD (NM_002225.3), KCNJ11 (NM_000525.3), LAMA2 (NM_000426.3), LAMA3 (NM_000227.4), LAMB3 (NM_000228.2), LAMC2 (NM_005562.2), LCA5 (NM_181714.3), LDLR (NM_000527.4), LDLRAP1 (NM_015627.2), LHX3 (NM_014564.4), LIFR (NM_002310.5), LIPA (NM_000235.3), LOXHD1 (NM_144612.6), LPL (NM_000237.2), LRPPRC (NM_133259.3), MAN2B1 (NM_000528.3), MCOLN1 (NM_020533.2), MED17 (NM_004268.4), MESP2 (NM_001039958.1), MFSD8 (NM_152778.2), MKS1 (NM_017777.3), MLC1 (NM_015166.3), MMAA (NM_172250.2), MMAB (NM_052845.3), MMACHC (NM_015506.2), MMADHC (NM_015702.2), MPI (NM_002435.2), MPL (NM_005373.2), MPV17 (NM_002437.4), MTHFR (NM_005957.4), MTRR (NM_002454.2), MTTP (NM_000253.3), MUT (NM_000255.3), MYO7A (NM_000260.3), NAGLU (NM_000263.3), NAGS (NM_153006.2), NBN (NM_002485.4), NDRG1 (NM_006096.3), NDUFAF5 (NM_024120.4), NDUFS6 (NM_004553.4), NEB (NM_001271208.1), NPC1 (NM_000271.4), NPC2 (NM_006432.3), NPHS1 (NM_004646.3), NPHS2 (NM_014625.3), NR2E3 (NM_014249.3), NTRK1 (NM_001012331.1), OAT (NM_000274.3), OPA3 (NM_025136.3), PAH (NM_000277.1), PC (NM_000920.3), PCCA (NM_000282.3), PCCB (NM_000532.4), PCDH15 (NM_033056.3), PDHB (NM_000925.3), PEX1 (NM_000466.2), PEX10 (NM_153818.1), PEX12 (NM_000286.2), PEX2 (NM_000318.2), PEX6 (NM_000287.3), PEX7 (NM_000288.3), PFKM (NM_000289.5), PHGDH (NM_006623.3), PKHD1 (NM_138694.3), PMM2 (NM_000303.2), POMGNT1 (NM_017739.3), PPT1 (NM_000310.3), PROP1 (NM_006261.4), PSAP (NM_002778.3), PTS (NM_000317.2), PUS1 (NM_025215.5), PYGM (NM_005609.3), RAB23 (NM_183227.2), RAG2 (NM_000536.3), RAPSN (NM_005055.4), RARS2 (NM_020320.3), RDH12 (NM_152443.2), RMRP (NR_003051.3), RPE65 (NM_000329.2), RPGRIP1L (NM_015272.2), RTEL1 (NM_001283009.1), SACS (NM_014363.5), SAMHD1 (NM_015474.3), SEPSECS (NM_016955.3), SGCA (NM_000023.2), SGCB (NM_000232.4), SGCG (NM_000231.2), SGSH (NM_000199.3), SLC12A3 (NM_000339.2), SLC12A6 (NM_133647.1), SLC17A5 (NM_012434.4), SLC22A5 (NM_003060.3), SLC25A13 (NM_014251.2), SLC25A15 (NM_014252.3), SLC26A2 (NM_000112.3), SLC26A4 (NM_000441.1), SLC35A3 (NM_012243.2), SLC37A4 (NM_001164277.1), SLC39A4 (NM_130849.3), SLC4A11 (NM_032034.3), SLC7A7 (NM_001126106.2), SMARCAL1 (NM_014140.3), SMN1 (NM_000344.3), SMPD1 (NM_000543.4), STAR (NM_000349.2), SUMF1 (NM_182760.3), TAT (NM_000353.2), TCIRG1 (NM_006019.3), TECPR2 (NM_014844.3), TFR2 (NM_003227.3), TGM1 (NM_000359.2), TH (NM_199292.2), TMEM216 (NM_001173990.2), TPP1 (NM_000391.3), TRMU (NM_018006.4), TSFM (NM_001172696.1), TTPA (NM_000370.3), TYMP (NM_001953.4), USH1C (NM_005709.3), USH2A (NM_206933.2), VPS13A (NM_033305.2), VPS13B (NM_017890.4), VPS45 (NM_007259.4), VRK1 (NM_003384.2), VSX2 (NM_182894.2), WNT10A (NM_025216.2), XPA (NM_000380.3), XPC (NM_004628.4), ZFYVE26 (NM_015346.3).





- This report only includes variants that have a clinically significant association with the conditions tested as of the report date. Variants of uncertain significance, benign variants, and likely benign variants are not included in this report. However, if additional evidence becomes available to indicate that the clinical significance of a variant has changed, Invitae may update this report and provide notification.
- A PMID is a unique identifier referring to a published, scientific paper. Search by PMID at http://www.ncbi.nlm.nih.gov/pubmed.
- An rsID is a unique identifier referring to a single genomic position, and is used to associate population frequency information with sequence changes at that position. Reported population frequencies are derived from a number of public sites that aggregate data from large-scale population sequencing projects, including ExAC (http://exac.broadinstitute.org) and dbSNP (http://ncbi.nlm.nih.gov/SNP).

Disclaimer

DNA studies do not constitute a definitive test for the selected condition(s) in all individuals. It should be realized that there are possible sources of error. Errors can result from trace contamination, rare technical errors, rare genetic variants that interfere with analysis, recent scientific developments, and alternative classification systems. This test should be one of many aspects used by the healthcare provider to help with a diagnosis and treatment plan, but it is not a diagnosis itself. This test was developed and its performance characteristics determined by Invitae. It has not been cleared or approved by the FDA. The laboratory is regulated under the Clinical Laboratory Improvement Act (CLIA) as qualified to perform high-complexity clinical tests (CLIA ID: 05D2040778). This test is used for clinical purposes. It should not be regarded as investigational or for research.

Limitations

- Based on validation study results, this assay achieves >99% analytical sensitivity and specificity for single nucleotide variants, insertions and deletions <15bp in length, and exon-level deletions and duplications. Invitae's methods also detect insertions and deletions larger than 15bp but smaller than a full exon but sensitivity for these may be marginally reduced. Invitae's deletion/duplication analysis determines copy number at a single exon resolution at virtually all targeted exons. However, in rare situations, single-exon copy number events may not be analyzed due to inherent sequence properties or isolated reduction in data quality. Certain types of variants, such as structural rearrangements (e.g. inversions, gene conversion events, translocations, etc.) or variants embedded in sequence with complex architecture (e.g. short tandem repeats or segmental duplications), may not be detected. Additionally, it may not be possible to fully resolve certain details about variants, such as mosaicism, phasing, or mapping ambiguity. Unless explicitly guaranteed, sequence changes in the promoter, non-coding exons, and other non-coding regions are not covered by this assay. Please consult the test definition on our website for details regarding regions or types of variants that are covered or excluded for this test. This report reflects the analysis of an extracted genomic DNA sample. While this test is intended to reflect the analysis of extracted genomic DNA from a referred patient, in very rare cases the analyzed DNA may not represent that individual's constitutional genome, such as in the case of a circulating hematolymphoid neoplasm, bone marrow transplant, blood transfusion, chimerism, culture artifact or maternal cell contamination.</p>
- RPGRIP1L: Sequencing analysis is not offered for exon 23. GBA: c.84dupG (p.Leu29Alafs*18), c.115+1G>A (Splice donor), c.222_224delTAC (p.Thr75del), c.475C>T (p.Arg159Trp), c.595_596delCT (p.Leu199Aspfs*62), c.680A>G (p.Asn227Ser), c.721G>A (p.Gly241Arg), c.754T>A (p.Phe252lle), c.1226A>G (p.Asn409Ser), c.1246G>A (p.Gly416Ser), c.1263_1317del (p.Leu422Profs*4), c.1297G>T (p.Val433Leu), c.1342G>C (p.Asp448His), c.1343A>T (p.Asp448Val), c.1448T>C (p.Leu483Pro), c.1504C>T (p.Arg502Cys), c.1505G>A (p.Arg502His), c.1603C>T (p.Arg535Cys), c.1604G>A (p.Arg535His) variants only. Rarely, sensitivity to detect these variants may be reduced. When sensitivity is reduced, zygosity may be reported as "unknown". NBN: Deletion/duplication analysis is not offered for exons 15-16. USH1C: Deletion/duplication analysis is not offered for exons 5-6. CYP21A2: Analysis includes the most common variants (c.92C>T(p.Pro31Leu), c.293-13C>G (intronic), c.332_339delGAGACTAC (p.Gly111Valfs*21), c.518T>A (p.Ile173Asn), c.710T>A (p.Ile237Asn), c.713T>A (p.Val238Glu), c.719T>A (p.Met240Lys), c.844G>T (p.Val282Leu), c.923dupT (p.Leu308Phefs*6), c.955C>T (p.Gln319*), c.1069C>T(p.Arg357Trp), c.1360C>T (p.Pro454Ser) and the 30Kb deletion) as well as select rare HGMD variants only (list available upon request). Full gene duplications are reported only in the presence of a pathogenic variant(s). When a duplication and a pathogenic variant(s) is identified, phase (cis/trans) cannot be determined. Full gene deletion analysis is not offered. Sensitivity to detect these variants, if they result from complex gene conversion/fusion events, may be reduced. FAH: Deletion/duplication analysis is not offered for exon 14. GALC: Deletion/duplication analysis is not offered for exon 6. HBA1/2: This assay is designed to detect deletions and duplications of HBA1 and/or HBA2, resulting from the -alpha20.5, --MED, --SEA, --FIL/--THAI, -alpha3.7, -alpha4.2, anti3.7 and anti4.2. Sensitivity to detect other copy number variants may be reduced. Detection of overlapping deletion and duplication events will be limited to combinations of events with significantly differing boundaries. In addition, deletion of the enhancer element HS-40 and





the sequence variant, Constant Spring (NM_000517.4:c.427T>C), can be identified by this assay. HBA2: Sequencing analysis is not offered for exons 1-2. NEB: Deletion/duplication analysis is not offered for exons 82-105. NEB variants in this region with no evidence towards pathogenicity are not included in this report, but are available upon request. TSFM: Sequencing analysis is not offered for exon 5. MMADHC: Deletion/ duplication analysis is not offered for exons 5-6. OAT: Deletion/duplication analysis is not offered for exon 2. VPS13A: Deletion/duplication analysis is not offered for exons 2-3, 27-28. MTHFR: The NM_005957.4:c.665C>T (p.Ala222Val) (aka 677C>T) and c.1286A>C (p.Glu429Ala) (aka 1298A>C) variants are not reported in our primary report. SMN1 or SMN2: NM_000344.3:c.*3+80T>G variant only. SMN1: Systematic exon numbering is used for all genes, including SMN1, and for this reason the exon typically referred to as exon 7 in the literature (PMID: 8838816) is referred to as exon 8 in this report. This assay unambiguously detects SMN1 exon 8 copy number. The presence of the g.27134T>G variant (also known as c.*3+80T>G) is reported if SMN1 copy number = 2. ALG6: Deletion/duplication analysis is not offered for exons 11-12. COL27A1: Deletion/duplication analysis is not offered for exons 46-47.

This report has been reviewed and approved by:

megh

Mei Zhu, Ph.D., FACMG Clinical Molecular Geneticist